COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) Lancet 360: 1071-3 Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. McAdam BF, Byrne D, Morrow JD, Oates JA (2005) Circulation 112: 1024-9 Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF (2002) Circulation 105: 1816-23 The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide. Sánchez-Pedregal VM, Kubicek K, Meiler J, Lyothier I, Paterson I, Carlomagno T (2006) Angew Chem Int Ed Engl 45: 7388-94 Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ (2003) Cancer Res 63: 1748-51 Are all COX-2 inhibitors created equal? Chang IJ, Harris RC (2005) Hypertension 45: 178-80 Mitochondrial Cyclophilin D in Vascular Oxidative Stress and Hypertension. Itani HA, Dikalova AE, McMaster WG, Nazarewicz RR, Bikineyeva AT, Harrison DG, Dikalov SI (2016) Hypertension 67: 1218-27 Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Crofford LJ (2002) Curr Opin Rheumatol 14: 225-30 Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF (2005) J Mol Cell Cardiol 39: 443-52 Identification of platelet-activating factor as the inflammatory lipid mediator in CCl4-metabolizing rat liver. Marathe GK, Harrison KA, Roberts LJ, Morrow JD, Murphy RC, Tjoelker LW, Prescott SM, Zimmerman GA, McIntyre TM (2001) J Lipid Res 42: 587-96 Quinides of roasted coffee enhance insulin action in conscious rats. Shearer J, Farah A, de Paulis T, Bracy DP, Pencek RR, Graham TE, Wasserman DH (2003) J Nutr 133: 3529-32 Growth phase regulation of flaA expression in Helicobacter pylori is luxS dependent. Loh JT, Forsyth MH, Cover TL (2004) Infect Immun 72: 5506-10 Intercellular communication in Helicobacter pylori: luxS is essential for the production of an extracellular signaling molecule. Forsyth MH, Cover TL (2000) Infect Immun 68: 3193-9 Lichenoid eruption associated with orlistat. Sergeant A, Milne G, Shaffrali F (2006) Br J Dermatol 154: 1020-1 Emerging from the shadow of Vioxx. Lindsley CW (2007) Curr Top Med Chem 7: 739 Quantitative effect of luxS gene inactivation on the fitness of Helicobacter pylori. Lee WK, Ogura K, Loh JT, Cover TL, Berg DE (2006) Appl Environ Microbiol 72: 6615-22 Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, Sosman J, Vokes EE (2001) Invest New Drugs 19: 249-54 To Avoid Chasing Incorrect Chemical Structures of Chiral Compounds: Raman Optical Activity and Vibrational Circular Dichroism Spectroscopies. Polavarapu PL, Covington CL, Raghavan V (2017) Chemphyschem 18: 2459-2465 Absolute Configuration of (-)-Centratherin, a Sesquiterpenoid Lactone, Defined by Means of Chiroptical Spectroscopy. Junior FM, Covington CL, de Albuquerque AC, Lobo JF, Borges RM, de Amorim MB, Polavarapu PL (2015) J Nat Prod 78: 2617-23 The molecular receptive range of a lactone receptor in Anopheles gambiae. Pask GM, Romaine IM, Zwiebel LJ (2013) Chem Senses 38: 19-25 What are the risks and the benefits of current and emerging weight-loss medications? Robinson JR, Niswender KD (2009) Curr Diab Rep 9: 368-75 In Helicobacter pylori auto-inducer-2, but not LuxS/MccAB catalysed reverse transsulphuration, regulates motility through modulation of flagellar gene transcription. Shen F, Hobley L, Doherty N, Loh JT, Cover TL, Sockett RE, Hardie KR, Atherton JC (2010) BMC Microbiol 10: 210 COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J (2003) Pharmacoepidemiol Drug Saf 12: 67-70 High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA (2004) Pharmacoepidemiol Drug Saf 13: 339-43
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.